BeyondSpring Inc. announced on March 27, 2025, the filing of its annual report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The report provides a comprehensive overview of the company's financial performance and strategic developments for the past year.
Key highlights from the year included the publication of final Phase 3 data for Plinabulin in *The Lancet Respiratory Medicine* in September 2024. This publication demonstrated an overall survival benefit in second- and third-line EGFR wild-type non-small cell lung cancer (NSCLC) patients when Plinabulin was combined with docetaxel, compared to docetaxel alone. This pivotal data supports Plinabulin's potential in a significant oncology indication.
Additionally, SEED Therapeutics, a subsidiary of BeyondSpring, entered into a targeted protein degradation research collaboration with Eisai Co. Ltd., with potential payments to SEED of up to $1.5 billion. SEED also completed a $24 million first close of its Series A-3 financing. These developments underscore the value and progress of BeyondSpring's equity interest in SEED.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.